Syndax Pharmaceuticals SNDX Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's business segments — net income loss?
- Syndax Pharmaceuticals (SNDX) reported business segments — net income loss of -$42.67M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — net income loss changed year-over-year?
- Syndax Pharmaceuticals's business segments — net income loss increased by 49.7% year-over-year, from -$84.85M to -$42.67M.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — net income loss?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — net income loss has grown at a 24.1% compound annual growth rate (CAGR), from -$149.34M to -$285.42M.
- What does business segments — net income loss mean?
- This metric represents the total profit or loss generated by the business segment after accounting for all revenues, operating expenses, research and development costs, and other non-operating items. It serves as the primary indicator of the segment's financial viability and its ability to generate sustainable returns from its therapeutic pipeline. For clinical-stage companies, this figure highlights the burn rate and the financial efficiency of the segment's drug development programs.